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Introduction
Esophageal cancer comprises a significant portion of gas-
trointestinal malignancies with an annual incidence of 
approximately 17,000 in the United States and over 450,000 
worldwide [1, 2]. Despite improvements in outcome over 
time, annual death rates continue to nearly match annual 
incidence and prognosis remains poor with an overall 
survival of around 20% at 5 years for locoregional disease 
[1, 2]. Surgical resection has been a key component of 
definitive therapy; however, its utilization is often tempered 
by potential morbidity and mortality associated with 
esophagectomy [3–5]. For surgically fit patients, a standard 
of care for locally advanced disease is trimodality therapy 
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Abstract
For elderly patients with locally advanced esophageal cancer, therapeutic approaches 
and outcomes in a modern cohort are not well characterized. Patients ≥70 years 
old with clinical stage II and III esophageal cancer diagnosed between 1998 and 
2012 were identified from the National Cancer Database and stratified based on 
treatment type. Variables associated with treatment utilization were evaluated using 
logistic regression and survival evaluated using Cox proportional hazards analysis. 
Propensity matching (1:1) was performed to help account for selection bias. A 
total of 21,593 patients were identified. Median and maximum ages were 77 and 
90, respectively. Treatment included palliative therapy (24.3%), chemoradiation 
(37.1%), trimodality therapy (10.0%), esophagectomy alone (5.6%), or no therapy 
(12.9%). Age ≥80 (OR 0.73), female gender (OR 0.81), Charlson–Deyo comorbidity 
score ≥2 (OR 0.82), and high- volume centers (OR 0.83) were associated with a 
decreased likelihood of palliative therapy versus no treatment. Age ≥80 (OR 0.79) 
and Clinical Stage III (OR 0.33) were associated with a decreased likelihood, while 
adenocarcinoma histology (OR 1.33) and nonacademic cancer centers (OR 3.9), 
an increased likelihood of esophagectomy alone compared to definitive chemora-
diation. Age ≥80 (OR 0.15), female gender (OR 0.80), and non- Caucasian race 
(OR 0.63) were associated with a decreased likelihood, while adenocarcinoma his-
tology (OR 2.10) and high- volume centers (OR 2.34), an increased likelihood of 
trimodality therapy compared to definitive chemoradiation. Each treatment type 
demonstrated improved survival compared to no therapy: palliative treatment (HR 
0.49) to trimodality therapy (HR 0.25) with significance between all groups. Any 
therapy, including palliative care, was associated with improved survival; however, 
subsets of elderly patients with locally advanced esophageal cancer are less likely 
to receive aggressive therapy. Care should be taken to not unnecessarily deprive 
these individuals of treatment that may improve survival.
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with neoadjuvant concurrent chemoradiation followed by 
esophagectomy based on improved outcomes compared 
to surgery alone [6, 7].
When aggressive combined- modality therapy is a stand-
ard treatment approach as it is for esophageal cancer, 
the elderly patient in particular presents a therapeutic 
challenge. The decision whether to offer definitive therapy, 
or any therapy at all, is determined in the context of an 
increased risk of toxicity and a more limited life expec-
tancy. Studies examining patterns or outcomes of treatment 
for esophageal cancer in this population are limited, and 
most are small, single- institution experiences. In this set-
ting, esophagectomy in the elderly is less utilized and 
associated with a potential increase in postoperative com-
plications, but is feasible in selected patients with accept-
able outcomes [5, 8–10]. Definitive chemoradiation is also 
more infrequently considered in the elderly, yet treatment 
appears to be well tolerated with efficacy comparable to 
younger patients [11–14]. Population- based analyses have 
elucidated some broad trends and outcomes in this older 
population and these largely mirror the single- institution 
studies [15, 16]. However, these studies predate the defini-
tive treatment paradigm shift to neoadjuvant therapy and 
thus may be less applicable to a modern cohort of elderly 
patients.
To address current trends and predictors of treatment 
utilization and associated outcomes, we queried the 
National Cancer Database (NCDB). A joint program of 
the Commission on Cancer of the American College of 
Surgeons and the American Cancer Society, the NCDB 
compiles data from over 1500 commission- accredited can-
cer programs and captures about 70% of newly diagnosed 
patients with cancer in the United States annually. Here, 
we examine elderly patients (≥70 years old) with locally 
advanced esophageal cancer to evaluate how this popula-
tion is being managed in the modern era and what factors 
influence specific treatment choices. Modalities evaluated 
were no treatment delivered, palliative therapies, definitive 
chemoradiation, esophagectomy alone, and trimodality, 
with the primary aim to compare overall survival between 
these groups. Secondary aims included identifying variables 
independently associated with receiving each modality.
Material and Methods
Patients
The NCDB Participant User File for esophageal cancer 
was used to identify clinical stage II and III patients 
≥70 years old diagnosed between 1998 and 2012. As patients 
and centers are deidentified by the NCDB, this study was 
deemed exempt by the Washington University School of 
Medicine Institutional Review Board.
Using the NCDB data dictionary, patient characteristics 
were dichotomized into: Caucasian or non- Caucasian; popu-
lation type of metropolitan, urban, or rural; average income 
<$38,000 or ≥$38,000 by zip code; education level of ≥21% 
or <21% in zip code with no high school diploma; and 
insurance status of Medicare, Medicaid, private, or other 
government (e.g., Federal insurance or Tricare). Using 
Figure 1. Consort diagram.
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ICD- 0- 3 codes, histology subtypes were dichotomized as 
either adenocarcinoma or squamous cell of the 
esophagus.
Patients were excluded from analysis if they had unknown 
clinical stage, discordant clinical stage (recorded clinical 
T/N stage did not match recorded overall clinical stage), 
metastatic disease, or received endoscopic or ablative 
therapy. A Consolidated Standards of Reporting Trials 
(CONSORT) diagram is shown in Figure 1. An interquartile 
range of center volume by the number of years a center 
contributed to the NCDB was calculated. Centers in the 
top quartile were labeled “high- volume” centers, all others 
were labeled “low- volume” centers. Patients were considered 
to have received concurrent chemoradiation if the date 
from diagnosis to initiation of systemic therapy and the 
date from diagnosis to initiation of radiation therapy were 
within a 14- day limit. If these dates were separated by 
>14 days, they were considered to have received sequential 
therapy. For the purposes of this analysis, palliative therapy 
was defined as any treatment not considered definitive 
therapy for curative intent for locally advanced disease 
and included: chemotherapy only, radiation therapy only, 
or sequential chemotherapy/radiation therapy. Trimodality 
therapy was defined as receipt of neoadjuvant chemoradia-
tion therapy followed by esophagectomy.
Statistical analysis
Descriptive statistics of continuous variables were expressed 
as mean ± standard error of the mean. Univariate com-
parisons included independent sample t- tests to compare 
normally distributed continuous variables and chi- square 
analysis for comparisons of categorical data. Stepwise 
backwards logistic regression was used to identify variables 
independently associated with receiving palliative therapy 
(relative to no treatment) and trimodality therapy (relative 
to definitive chemoradiation) as this method allows for 
more robust analysis to determine significance in a large 
cohort. Criteria for entry into the logistic regression model 
included a P value of <0.05 on univariate analysis. Kaplan–
Meier analysis was performed to compare median overall 
survival outcomes by therapy type (including no treat-
ment), with log- rank testing. A Cox proportional hazards 
model was created to identify variables independently 
associated with increased risk of overall mortality.
To assist in controlling for patient and tumor factors 
potentially involved in selection bias, two propensity- 
matched analyses were performed: (1) matching no treat-
ment patients to those receiving palliative treatment, (2) 
matching definitive chemoradiation patients to those 
receiving trimodality therapy, (3) matching definitive 
chemoradiation patients to those receiving esophagectomy 
alone. Patients were matched on the following variables: 
age (as a continuous variable, to better account for pos-
sible unmeasured age- related comorbidities), sex, race, 
distance from treatment center, center type, center volume, 
insurance type, income, education level, population type, 
Charlson- Deyo score, histology type, clinical stage, T stage, 
tumor grade, and tumor location. After propensity score 
calculation using logistic regression, patients were matched 
1:1 using nearest neighbor matching with a caliper distance 
of 0.20 of the standard deviation of the logit of the pro-
pensity score. Postmatching diagnostics included analysis 
of the standardized mean differences between the matching 
variables. For both matched analyses performed, no inter-
actions demonstrated a standardized mean difference >0.20. 
Kaplan–Meier analysis was again performed among these 
matched pairs with log- rank testing.
P values <0.05 were considered statistically significant. 
Statistical analyses were performed in SPSS 23.0 for 
Windows (SPSS Inc, Chicago IL, 2013).
Results
Patient characteristics
A total of 21,593 patients with locally advanced esophageal 
cancer age ≥70 were analyzed (Table 1). The median age 
was 77 and patients were predominantly Caucasian (89.0%), 
male (72.0%), and of a higher educational (82.1%) and 
income (79.9%) status. There was a near- even split between 
clinical stage II (52.6%) and stage III (47.4%) patients. 
The majority of tumors were located in the lower third 
of the esophagus (56.7%) and were of adenocarcinoma 
histology (52.1%).
Treatment utilization and outcome
Among the treatment categories analyzed, definitive (con-
current) chemoradiation was the most common (37.1%) 
followed by palliative therapy (24.3%). In the definitive 
chemoradiation group, the mean elapsed time of radiation 
treatment was 42.0 ± 0.3 days and most (70.6%) received 
multiagent chemotherapy. Within the palliative therapy 
group, the majority received radiation alone (50.7%), fol-
lowed by sequential chemoradiation (34.1%) and chemo-
therapy alone (15.2%). Ten percent received trimodality 
therapy. For the neoadjuvant portion, mean elapsed time 
of radiation treatment was 39.0 ± 0.8 days with 80.1% 
receiving multiagent chemotherapy. Trends in utilization 
of each over time are shown in Figure S1. Between 1998 
and 2012, as compared to prior years, trimodality use 
steadily increased, while esophagectomy alone increased 
in early years, but declined significantly after 2009. Between 
age groups within the elderly cohort, there was hetero-
geneity in treatment utilization as well (Table 2). Notably, 
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patients aged 80 and older were significantly more likely 
to receive palliative therapy or no treatment and less likely 
to receive trimodality therapy or surgery alone.
Overall survival by treatment type is shown in Figure 2. 
Patients who underwent trimodality therapy had the most 
favorable outcome with a median survival of 26.8 months 
(95% CI: 24.9–28.7) followed by esophagectomy alone at 
19.3 months (95% CI: 17.1–21.5) and chemoradiation at 
14.0 months (95% CI: 13.5–14.5). Median survival for pal-
liative therapy was 9.7 months (95% CI: 9.3–10.1). Those 
who did not undergo any tumor- directed therapy had a 
median survival of 3.6 months (95% CI: 3.4–3.9). When 
separated by histology, survival trends by treatment type 
were generally comparable to the overall cohort with squa-
mous cell carcinoma patients often trending toward worse 
survival than their adenocarcinoma counterparts (Fig. 3). As 
with the full cohort, the most favorable outcomes were seen 
with trimodality with median survival for squamous cell 
carcinoma of 24.8 months (95% CI: 19.7–30.0) and for 
adenocarcinoma of 27.7 months (95% CI: 25.5–30.0), and 
the least favorable outcomes were with no treatment with 
median survivals of 2.9 months (95% CI: 2.6–3.2) and 
4.6 months (95% CI: 4.1–5.1), respectively. Interestingly, for 
squamous cell carcinoma only, median survival for esophagec-
tomy alone (15.9 months, 95% CI: 12.3–19.5), though slightly 
higher than 14.3 months for concurrent chemoradiation, was 
not statistically significant (P = 0.44). Otherwise, median 
survivals were statistically different for the remaining treat-
ment comparisons for squamous cell carcinoma and all 
treatment comparisons for adenocarcinoma (P < 0.001).
Predictors of utilization – palliative therapy 
versus no treatment
On univariate analysis, the palliative therapy group was 
younger (age 70–79, 57.9% vs. 49.7%), more likely to be 
male (67.9% vs. 64.2%) and clinical stage II (52.0% vs. 
45.9%), and lived closer to their treatment center (24.9 
vs. 31.7 miles) (Table S1). On multivariate logistic regres-
sion, age ≥ 80 (OR 0.73), female gender (OR 0.81), Charlson- 
Deyo comorbidity score ≥1 (OR 0.82–0.85), clinical stage 
III (OR 0.80), and receiving treatment at a high- volume 
center (OR 0.83) were independently associated with a 
decreased likelihood of receiving palliative therapy (Table 3). 
Only higher levels of education (OR 1.25) or insurance 
status including private insurance (OR 1.55) and Medicare 
(OR 1.77) were independently associated with receiving 
palliative therapy. After propensity matching (1105 patient 
pairs), there was a significant improvement in median sur-
vival from 3.5 months (95% CI: 3.1–3.9) in the no treat-
ment group to 9.9 months (95% CI: 9.1–10.6) in the 
palliative therapy group, P < 0.001 (Figs. S2 and S3).
Predictors of utilization – trimodality 
therapy versus definitive chemoradiation
On univariate analysis, the trimodality group was over-
whelmingly younger (age 70–79, 93.3% vs. 68.8%) and 
more likely to be male (83.5% vs. 73.0%), Caucasian 
(95.9% vs. 90.0%), and treated at a high- volume center 
Table 1. Demographics and clinical characteristics for elderly clinical 
stage II and III esophageal cancer patients from the NCDB diagnosed 
between 1998 and 2012.
Demographic or clinical characteristic Patients (N = 21,593)












Income (by zip code)
<$38,000 4348 (20.1%)
≥$38,000 17,245 (79.9%)
Education (by zip code)
≥21% with no high school diploma 3874 (17.9%)
<21% with no high school diploma 17,719 (82.1%)
Metropolitan population type 16,991 (78.7%)













Squamous cell carcinoma 9068 (42.0%)
Unknown 1276 (5.9%)
Tumor location
Cervical esophagus 724 (3.4%)
Upper third 1303 (6.0%)
Middle third 3545 (16.4%)
Lower third 12,239 (56.7%)
Unknown 3782 (17.5%)
Treatment type
No treatment 2787 (12.9%)
Palliative therapy 5252 (24.3%)
Concurrent chemoradiation 8010 (37.1%)
Esophagectomy alone 1215 (5.6%)
Trimodality therapy 2159 (10.0%)
Unknown 2170 (10.1%)
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(40.7% vs. 22.0%). Trimodality was more often associated 
with adenocarcinoma histology (72.6% vs. 51.3%) and 
tumors in the lower third of the esophagus (77.8% vs. 
56.7%) (Table S2). Multivariate analysis confirmed that 
patients who were ≥80 years old (OR 0.15), female (OR 
0.80), or non- Caucasian (OR 0.63) were significantly less 
likely to receive trimodality, while those with adenocar-
cinoma histology (OR 2.10) or treated at a high- volume 
center (OR 2.34) were more likely to receive trimodality 
(Table 3). After propensity matching (955 patient pairs), 
there was a significant improvement in median survival 
from 15.6 months (95% CI: 14.3–16.9) in the concurrent 
chemoradiation group to 27.6 months (95% CI: 24.7–30.4) 
among trimodality patients, P < 0.001 (Figs. S4 and S5).
Because age was a strong predictor of not receiving 
trimodality therapy, we then explored perioperative mor-
bidity and mortality between age groups. We found that 
mean length of hospital stay (12.8 vs. 14.3 days, P = 0.25) 
and 30- day readmission rates (6.7% vs. 7.0%, P = 0.90) 
were not significantly different. On the other hand, 30- 
day and 90- day mortality were worse for patients ≥80 years 
old (10.4% vs. 5.5%, P = 0.03, and 23.7% vs. 14.2%, 
P = 0.006, respectively), though the number of these older 
patients is small (n = 145) relative to the entire cohort 
(Table S3).
Predictors of utilization – esophagectomy 
alone versus definitive chemoradiation
While its use appears to have declined in recent years 
and trimodality is the more common surgical approach 
for definitive therapy in our cohort, esophagectomy alone 
is still utilized as definitive therapy in a portion of patients. 
Therefore, we also compared patients receiving esophagec-
tomy alone to those receiving concurrent chemoradiation 
in the definitive setting. On univariate analysis, the 
esophagectomy group was younger (age 70–79, 75.1% vs. 
69.0%), more likely to be male (77.4% vs. 72.3%), Caucasian 
(95.4% vs. 89.9%), and live farther from the treatment 
center (54.2 vs. 32.7 miles). As with trimodality, esophagec-
tomy alone was also more often associated with adeno-
carcinoma histology (71.5% vs. 52.4%) and tumors in 
the lower third of the esophagus (81.6% vs. 68.8%) (Table 
S4). On multivariate logistic regression, age ≥80 (OR 0.79), 
clinical stage III (OR 0.33), and tumors in the upper and 
middle third of the esophagus (OR 0.31–0.69) were inde-
pendently associated with a decreased likelihood, while 
those with a Charlson- Deyo comorbidity score ≥1 (OR 
1.31–1.47), adenocarcinoma histology (OR 1.33), and being 
Table 2. Distribution of treatments by age group.





No treatment 1386 (9.5%) 1401 (20.0%) <0.001
Palliative therapy 3041 (20.9%) 2211 (31.5%)
Concurrent 
chemoradiation
5528 (37.9%) 2482 (35.4%)
Esophagectomy 
alone
912 (6.2%) 303 (4.3%)
Trimodality 
therapy
2014 (13.8%) 145 (2.1%)
Unknown 1699 (11.7%) 471 (6.7%)
Figure 2. Kaplan–Meier overall survival for elderly patients with locally advanced esophageal cancer stratified by type of treatment.
2891© 2017 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. 
Locoregional Esophagus Cancer in ElderlyG. Vlacich et al.
treated at a nonacademic cancer center (OR 3.9) were 
more likely to receive esophagectomy alone (Table 4). 
After propensity matching (697 patient pairs), there was 
a significant improvement in median survival from 
15.3 months (95% CI: 13.3–17.3) in the concurrent chemo-
radiation group to 19.8 months (95% CI: 16.5–23.2) among 
esophagectomy alone patients, P < 0.001 (Figs. S6 and 
S7).
Figure 3. Kaplan–Meier overall survival for elderly patients with locally advanced squamous cell carcinoma (A) or adenocarcinoma (B) of the esophagus 
stratified by type of treatment. *P value for only the comparison between esophagectomy alone and definitive concurrent chemoradiation in 
squamous cell carcinoma patients was 0.44. All other comparisons were statistically significant.
A  Squamous cell carcinoma
B  Adenocarcinoma
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Predictors of outcome
Risk factors for survival in the full elderly cohort were 
analyzed using a Cox proportional hazards model (Table 5). 
Increased overall mortality was associated with age ≥80 
(HR 1.21), a Charlson- Deyo comorbidity score ≥1 (HR 
1.21–1.41), and clinical stage III (HR 1.31, reference: stage 
II). Decreased mortality hazard was associated with female 
gender (HR 0.94), higher income (HR 0.93), receiving care 
at a high- volume center (HR 0.83), and adenocarcinoma 
histology (HR 0.94). Any tumor- directed therapy resulted 
in an independent relative improvement in survival over 
no treatment with more substantial mortality hazard reduc-
tion being achieved for each therapy type: palliative therapy 
(HR 0.49), definitive chemoradiation (HR 0.36), esophagec-
tomy (HR 0.31), and trimodality (HR 0.25), respectively.
Since adenocarcinoma histology was associated with 
improved survival and was a very strong predictor of 
receiving trimodality therapy, we then explored outcomes 
after definitive treatment based on histology. In the 
unmatched cohort, median overall survival with trimodality 
therapy was 27.7 months (95% CI: 25.5–30.0) in patients 
with adenocarcinoma and 24.8 months (95% CI: 19.7–30.0) 
in patients with squamous cell carcinoma; however, this 
difference was not statistically significant (P = 0.14, Figure 
S8A). For those treated with concurrent chemoradiation, 
median survivals of patients with adenocarcinoma and 
squamous cell histology, while significantly different, were 
days apart at 14.1 and 14.3 months, respectively (P < 0.001) 
(Table S5, Figure S8B).
Discussion
Among a modern cohort of elderly patients with locally 
advanced esophageal cancer, our results demonstrate sig-
nificant variability in treatment utilization and associated 
outcomes based on demographic and tumor characteristics. 
Treatment decisions were significantly influenced by age, 
sex, and treatment center patient volume. Race, comor-
bidities, education, income, and tumor location and his-
tology also impacted utilization in specific scenarios. 
Table 3. Multivariate analyses of predictors of treatment utilization for definitive and palliative therapy in elderly patients with locally advanced 
 esophageal cancer.
Variable Palliative Definitive
Palliative therapy versus no treatment Trimodality therapy versus concurrent chemoradiation
Odds ratio 95% CI P value Odds ratio 95% CI P value
Age ≥80 (Ref: 70–79) 0.73 0.65–0.81 <0.001 0.15 0.12–0.18 <0.001
Female gender 0.81 0.72–0.91 <0.001 0.80 0.69–0.92 0.03
High- volume center (Ref: 
low- volume)
0.83 0.73–0.95 0.008 2.34 2.07–2.65 <0.001
Tumor location (Ref: lower third)
Cervical 1.45 1.05–2.00 0.02 N/A
Upper third 1.13 0.90–1.41 0.03 2.76 1.82–4.19 <0.001
Lower third 1.01 0.86–1.18 0.90 4.09 2.74–6.11 <0.001
Unknown 0.79 0.68–0.91 0.001 2.41 1.59–3.67 <0.001
Education level: <21% 
with no high school 
diploma (Ref: ≥21%)
1.25 1.08–1.45 0.003
Insurance status (Ref: uninsured)
Private 1.55 0.87–2.76 0.14
Medicaid 1.52 0.73–3.14 0.26
Medicare 1.77 1.01–3.09 0.045
Other government 3.79 1.63–8.81 0.002
Charlson- Deyo score (Ref: 0)
1 0.85 0.74–0.97 0.015
≥2 0.82 0.67–0.99 0.04
Clinical stage III (Ref: stage II) 0.80 0.72–0.90 <0.001
Non- Caucasian race (Ref: 
Caucasian)
0.63 0.48 to 0.81 <0.001
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Tumor- directed therapy resulted in improved survival over 
no therapy with incremental improvement as the aggres-
siveness of treatment increased from palliative therapy to 
definitive chemoradiation to surgical management of 
disease.
Within the elderly cohort, age was one of the strongest 
predictors for treatment utilization and survival. Patients 
≥80 years old were more likely to receive no treatment 
in the nondefinitive setting and much less likely to receive 
trimodality therapy and esophagectomy alone when treated 
definitively. Underlying these differences is likely a com-
bination of patient- related factors, physician bias, and 
clinical realities. Numerous studies across various malig-
nancies have shown that advanced age is associated with 
decreased referral to specialists, increased delivery of sub-
optimal therapy, and increased patient refusal of therapy 
[16–19]. Objective clinical reasons supporting a more 
cautious approach to older individuals include decreased 
stem- cell reserves and the presence of comorbidities impact-
ing drug absorption and/or metabolism [20, 21]. 
Additionally, esophagectomy has been associated with 
higher rates of perioperative mortality in the elderly [5]. 
Indeed, we observed a higher percentage of 30- and 90- 
day mortality in the ≥80 age group, though the absolute 
number of deaths is smaller than the 70–79- year- old group 
and the rates in the ≥80 group may be overestimated 
due to the relatively small number of patients in that 
age group (~6% of the trimodality cohort). Nevertheless, 
in appropriately selected individuals, morbidity and mor-
tality from esophagectomy is comparable to younger 
patients in other studies, even for octogenarians [22, 23]. 
As it relates to the impact on survival, our data support 
the use of more aggressive therapy, including surgery, in 
the elderly patient with locally advanced esophageal cancer. 
While patient selection can impact these findings, we do 
see consistent improvement in outcomes with more aggres-
sive therapy in matched cohorts as well.
Gender was also a predictor of treatment utilization and 
survival with women appearing to be treated less aggres-
sively. The presence and causes of gender disparities in 
cancer treatment are not well defined, in part because many 
malignancies are gender- specific. However, a SEER- based 
analysis on colorectal cancer patients found that women, 
particularly octogenarians, underwent less aggressive therapy 
than men [24]. Despite this, women in this study and in 
our cohort had improved survival [24]. Factors underlying 
this contradiction are not clear, especially since women in 
our cohort were older (mean age 78.2 vs. 77, P < 0.001). 
While a difference in death from intercurrent disease is 
likely a contributor, gender differences in disease progres-
sion and treatment response are an underexplored possibility. 
Our results argue that care should be taken not to avoid 
aggressive therapy in elderly females with locally advanced 
esophageal cancer as their survival is comparable if not 
improved from their male counterparts.
In our elderly cohort, a significant percentage (37.2%) 
is not given definitive therapy for locally advanced disease. 
Of these patients, we see a near threefold improvement 
in median survival with palliative treatment compared to 
no therapy. The benefit of a particular palliative strategy 
is difficult to ascertain due to the heterogeneity of treat-
ment approaches, but a large majority (~85%) received 
radiation therapy and nearly half received chemotherapy. 
Additionally, the improved survival with palliative therapy 
can be impacted by patient selection factors not well 
appreciated in the NCDB (e.g., performance status) or 
by including patients not expressly coded as palliative 
and thus potentially being treated more aggressively in a 
definitive- type manner. Nevertheless, any nonconcurrent 
Table 4. Multivariate analysis of predictors of esophagectomy alone 
compared to definitive chemoradiation.
Variable Odds ratio 95% CI P value
Age ≥80 (Ref: 70–79) 0.79 0.65–0.96 0.015
Clinical stage III (Ref: stage II) 0.33 0.27–0.40 <0.001
Charlson- Deyo score (Ref: 0)
1 1.31 1.07–1.61 0.01
≥2 1.47 1.07–2.04 0.02
Tumor location (Ref: lower third)
Upper third 0.31 0.19–0.51 <0.01




Nonacademic cancer center 
(Ref: academic center)
3.9 3.2–4.6 <0.001




95% CI P value
Age ≥80 (Ref: 70–79) 1.21 1.15–1.27 <0.001
Female Gender 0.94 0.90–0.98 0.009
Income ≥$38,000 (Ref: <$38,000) 0.93 0.88–0.98 0.006
Charlson- Deyo score (Ref: 0)
1 1.21 1.15–1.27 <0.001
≥2 1.42 1.31–1.53 <0.001
High- volume center  
(Ref: low- volume)
0.83 0.79–0.87 <0.001
Clinical stage III (Ref: stage II) 1.31 1.26–1.37 <0.001
Adenocarcinoma histology  
(Ref: squamous)
0.94 0.90–0.98 0.03
Treatment type (Ref: no treatment)
Palliative therapy 0.49 0.46–0.53 <0.001
Concurrent chemoradiation 0.36 0.34–0.39 <0.001
Esophagectomy alone 0.31 0.28–0.34 <0.001
Trimodality therapy 0.25 0.23–0.27 <0.001
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chemoradiation strategy is in practice a palliative therapy 
for locally advanced disease. And while the true benefit 
of palliative therapy is unclear, our data suggest that 
tumor- directed therapy, even potentially with modest treat-
ment such as radiation alone can have a significant impact 
on survival. Importantly, the impact of these therapies 
on quality of life is not well characterized and should 
continue to be an important variable in deciding whether 
or not to offer palliative treatment.
In the definitive setting, there has been a shift away 
from upfront esophagectomy to trimodality with neoad-
juvant chemoradiation, particularly after the CROSS trial 
demonstrated improved outcomes over surgery alone [7]. 
While patients over 75 years old were excluded in this 
study, this trend is nonetheless mirrored in our elderly 
cohort where we see increased utilization of trimodality 
from 2006 (6.7% of treatments) compared to 2012 (13.6%). 
In this regard, our cohort is more aligned with current 
practice than previous population- based analyses of elderly 
patients where only 7% received trimodality [15, 16]. Of 
note, the CROSS trial demonstrated a wider differential 
in median survival between trimodality and esophagectomy 
alone compared to our cohort (49 months vs. 24 months 
in the CROSS trial compared to 27 months vs. 19 months). 
This is most likely primarily due to the (intended) advanced 
age of our cohort with a 17- year increase in median age 
(60 vs. 77) and the increased likelihood of competing risks 
as a result, though trimodality still appears to be associ-
ated with an improved survival in these elderly patients. 
Nevertheless, a small percentage of patients (5.6%) were 
treated with esophagectomy alone, and this may be due 
to a preference for surgical management of locally advanced 
disease as an alternative to chemoradiation in patients who 
are not felt to be appropriate candidates for trimodality 
therapy. Among our entire cohort, patients treated with 
esophagectomy alone did exhibit improved overall survival 
over chemoradiation, though this benefit may be more 
apparent in those with adenocarcinoma specifically.
Among patients receiving trimodality, we see a strong 
histologic bias toward adenocarcinomas. While adenocar-
cinoma histology was also associated with improved sur-
vival, there was no difference in survival between histologies 
within the trimodality group. The improved hazards ratio 
for adenocarcinoma, therefore, is likely the results of 
increased (threefold) utilization of a more effective treat-
ment. Nevertheless, factors underlying this bias toward 
adenocarcinoma for trimodality are unclear. One possibility 
is the differences in tumor location and associated dif-
ferences in surgical approaches and complexities, and this 
may explain the bias toward adenocarcinoma in patients 
receiving esophagectomy alone as well. Squamous cell 
carcinomas are more often in the mid and proximal 
esophagus where surgery is more extensive or significantly 
morbid [25]. Other possibilities include the epidemiologic 
differences between the two histologies and the growing 
evidence that in squamous cell carcinoma, definitive 
chemoradiation can result is comparable survival to treat-
ments involving surgery [26–28]. Indeed, when we evalu-
ated overall survival in the full cohort by histology and 
examined squamous cell carcinoma specifically, esophagec-
tomy alone appears to offer no significant survival advantage 
over definitive chemoradiation.
Limitations of our study include the inability to reli-
ably account for important factors such as comorbidities 
and performance status. This limits our ability to account 
for important patient selection criteria in treatment uti-
lization, and can have a subsequent impact on survival 
analysis, though we attempted to mitigate this effect 
through propensity matching. Additionally, quality of life 
outcomes are an important determinant in this popula-
tion, but are unable to be garnered from the NCDB. 
Finally, in the elderly when there is more likelihood of 
competing comorbidities, the inability to ascertain disease 
or progression- free survival is a further limitation when 
evaluating the benefit of therapy. This effect is somewhat 
offset by the aggressiveness of locally advanced esophageal 
cancer (median survival of 2.2 years with trimodality) 
relative to the average life expectancy in this age group 
(4–17 years) [29].
In conclusion, our analysis of the NCDB demonstrates 
that elderly patients with clinical stage II and III esopha-
geal cancer exhibited a survival benefit from any tumor- 
directed therapy, including palliative treatment. The use 
of trimodality confers the largest survival benefit and 
its use has increased over time. Despite these improved 
outcomes with treatment, there are still numerous fac-
tors including age, gender, and histology as well as treat-
ment at high- or low- volume centers that significantly 
impact treatment utilization and care should be taken 
to avoid bias in determining the most appropriate therapy 
for the elderly patient with locally advanced esophageal 
cancer.
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Supporting Information
Additional supporting information may be found in the 
online version of this article:
Figure S1. Relative utilization of each treatment over 
time. For each treatment group, the percentage of patients 
in that group is plotted by year of diagnosis as a function 
of all patients receiving that treatment. Percentages gener-
ally increase over time as patient numbers increase, with 
the relative use of trimodality outpacing other treatment.
Figure S2. Kaplan–Meier overall survival from propensity- 
matched elderly patients with locally advanced esophageal 
cancer receiving palliative therapy or no treatment.
Figure S3. Dot- plot (A) and propensity histograms (B) 
for propensity- matched elderly patients with locally 
advanced esophageal cancer receiving palliative therapy 
or no treatment.
Figure S4. Kaplan–Meier overall survival from 
propensity- matched elderly patients with locally advanced 
esophageal cancer receiving concurrent chemoradiation or 
trimodality therapy.
Figure S5. Dot- plot (A) and propensity histograms (B) 
for propensity- matched elderly patients with locally 
advanced esophageal cancer receiving concurrent chemo-
radiation or trimodality therapy.
Figure S6. Kaplan–Meier overall survival from 
propensity- matched elderly patients with locally advanced 
esophageal cancer receiving concurrent chemoradiation or 
esophagectomy alone.
Figure S7. Dot- plot (A) and propensity histograms (B) 
for propensity- matched elderly patients with locally 
advanced esophageal cancer concurrent chemoradiation 
or esophagectomy alone.
Figure S8. Kaplan–Meier overall survival of elderly 
patients with locally advanced esophageal cancer receiving 
concurrent chemoradiation or trimodality by histology.
Table S1. Univariate analysis of predictors of palliative 
therapy. Within each variable, patients with unknown 
values were excluded and the number of remaining patients 
(n) was noted within each variable and treatment group 
when applicable.
Table S2. Univariate analysis of predictors of trimodality 
therapy. Within each variable, patients with unknown 
values were excluded and the number of remaining patients 
(n) was noted within each variable and treatment group 
when applicable.
Table S3. Perioperative outcomes in patients undergoing 
trimodality therapy by age group.
Table S4. Univariate analysis of predictors of esophagec-
tomy alone. Within each variable, patients with unknown 
values were excluded and the number of remaining patients 
(n) was noted within each variable and treatment group 
when applicable.
Table S5. Survival after definitive therapy based on 
tumor histology.
